Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 0.47 |
| ▸ | JAK2 | O60674 | 9/20 | 0.47 |
| ▸ | TYK2 | P29597 | 7/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 6/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207996 | 0.91 | LRRK2 (0.52) | JAK1JAK2TYK2HDAC6JAK3 | |
| SCHEMBL10167391 | 0.83 | JAK1 (0.49) | JAK1JAK2TYK2HDAC6JAK3 | |
| SCHEMBL31299827 | 0.82 | SYK (0.44) | JAK1JAK2TYK2JAK3MERTK | |
| SCHEMBL342907 | 0.82 | JAK1 (0.46) | JAK1JAK2TYK2HDAC6JAK3 | |
| SCHEMBL10167377 | 0.81 | BRD4 (0.49) | JAK2JAK3LRRK2 | |
| SCHEMBL10167421 | 0.81 | HDAC6 (0.48) | JAK1JAK2TYK2HDAC6JAK3 | |
| SCHEMBL15428749 | 0.80 | JAK1 (0.47) | JAK1JAK2TYK2HDAC6JAK3 | |
| SCHEMBL10167369 | 0.79 | SYK (0.40) | JAK1JAK2TYK2JAK3AXL | |
| SCHEMBL26109534 | 0.79 | JAK2 (0.42) | JAK1JAK2TYK2JAK3LRRK2 | |
| SCHEMBL10167370 | 0.78 | DRD2 (0.47) | JAK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011156698-A2 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | JAK1 79/4885JAK2 217/4885TYK2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.